Genetic instability promotes the acquisition of chromosomal imbalances in T1b and T1c breast adenocarcinomas

被引:13
|
作者
Blegen, H
Ghadimi, BM
Jauho, A
Zetterberg, A
Eriksson, E
Auer, G
Ried, T
机构
[1] NCI, Dept Genet, Div Clin Sci, NIH, Bethesda, MD 20892 USA
[2] Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, Div Cellular & Mol Anal, SE-17176 Stockholm, Sweden
来源
ANALYTICAL CELLULAR PATHOLOGY | 2001年 / 22卷 / 03期
关键词
D O I
10.1155/2001/126030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In order to evaluate biological and genetic properties of early breast carcinomas we analyzed microdissected tissue from 33 primary breast carcinomas stage T1b and T1c with respect to the nuclear DNA content, the expression pattern of Ki-67, cyclin A, p27(KIP1), p53 and p21(WAF1), and chromosomal gains and losses. The results show that T1b carcinomas (6-10 mm, n = 17) were frequently near-diploid (53%) with low proliferative activity and staining patterns of p53 and p21(WAF1) that suggest the presence of wild type protein. The majority (12/16) of the T1c tumors (11-20 mm), however, was aneuploid, and proliferative activity and p53 expression were increased. Larger tumor size correlated with an increasing number of chromosomal copy number changes and in particular with regional amplifications. High level copy number increases (amplifications), however, were found exclusively in the aneuploid tumors, Amplification events correlated with elevated cyclin A and reduced p27 expression, respectively. Our results suggest that the sequential acquisition of genomic imbalances during tumor progression is accelerated in aneuploid tumors, and may contribute to the increased malignancy potential.
引用
收藏
页码:123 / 131
页数:9
相关论文
共 50 条
  • [1] Biological and Prognostic Role of Tumor Size (T1a, T1b, T1c) in Stage I Breast Cancer (Experience of International Cooperation)
    Kolyadina, I. V.
    Poddubnaya, I. V.
    van de Velde, Cornelis J. H.
    Kuppen, Peter J. K.
    Bastiaannet, E.
    Komov, D. V.
    Karseladze, A. I.
    Ermilova, V. D.
    Vishnevskaya, Y. V.
    Frank, G. A.
    SOVREMENNYE TEHNOLOGII V MEDICINE, 2014, 6 (03) : 28 - 34
  • [2] Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer
    Fasano, Genevieve A.
    Bayard, Solange
    Chen, Yalei
    Varella, Leticia
    Cigler, Tessa
    Bensenhaver, Jessica
    Simmons, Rache
    Swistel, Alexander
    Marti, Jennifer
    Moore, Anne
    Andreopoulou, Eleni
    Ng, John
    Brandmaier, Andrew
    Formenti, Silvia
    Ali, Haythem
    Davis, Melissa
    Newman, Lisa
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 192 (01) : 163 - 173
  • [3] Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer
    Genevieve A. Fasano
    Solange Bayard
    Yalei Chen
    Leticia Varella
    Tessa Cigler
    Jessica Bensenhaver
    Rache Simmons
    Alexander Swistel
    Jennifer Marti
    Anne Moore
    Eleni Andreopoulou
    John Ng
    Andrew Brandmaier
    Silvia Formenti
    Haythem Ali
    Melissa Davis
    Lisa Newman
    Breast Cancer Research and Treatment, 2022, 192 : 163 - 173
  • [4] Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer
    Carbajal-Ochoa, Walter
    Bravo-Solarte, Daniela C.
    Bernal, Ana M.
    Anampa, Jesus D.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (02) : 257 - 269
  • [5] Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer
    Walter Carbajal-Ochoa
    Daniela C. Bravo-Solarte
    Ana M. Bernal
    Jesus D. Anampa
    Breast Cancer Research and Treatment, 2024, 203 : 257 - 269
  • [6] Long-term results of T1a, T1b and T1c invasive breast carcinomas in Japanese women: Validation of the UICC T1 subgroup classification
    Ichizawa, N
    Fukutomi, T
    Iwamoto, E
    Akashi-Tanaka, S
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2002, 32 (03) : 108 - 109
  • [7] Adjuvant chemotherapy outcomes of node negative, T1a, T1b, T1c hormone receptor-negative HER2-positive breast cancer patients
    Paul, Anu
    Shi, Runhua
    Peddi, Prakash
    Burton, Gary
    CANCER RESEARCH, 2017, 77
  • [8] The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer
    Johnson, Kai C. C.
    Ni, Ai
    Quiroga, Dionisia
    Pariser, Ashley C.
    Sudheendra, Preeti K.
    Williams, Nicole O.
    Sardesai, Sagar D.
    Cherian, Mathew
    Stover, Daniel G.
    Gatti-Mays, Margaret
    Ramaswamy, Bhuvaneswari
    Lustberg, Maryam
    Jhawar, Sachin
    Skoracki, Roman
    Wesolowski, Robert
    NPJ BREAST CANCER, 2024, 10 (01)
  • [9] Chemotherapy significantly improves long-term survival of small lesion node negative metaplastic breast carcinoma in T1c population rather than T1a and T1b
    Chen, Qitong
    Zhou, Qin
    He, Hongye
    He, Yeqing
    Yuan, Yunchang
    Zou, Qiongyan
    Yi, Wenjun
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [10] Chemotherapy significantly improves long-term survival of small lesion node negative metaplastic breast carcinoma in T1c population rather than T1a and T1b
    Qitong Chen
    Qin Zhou
    Hongye He
    Yeqing He
    Yunchang Yuan
    Qiongyan Zou
    Wenjun Yi
    Scientific Reports, 12